PubMed Health⌕ Search

Biomedical subjects

F M Debruyne

Publications and source records attributed to F M Debruyne.

At least 415 records · Page 23Linked to original sources
PubMed1987

Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.

We recruited 71 previously untreated patients with metastatic prostatic carcinoma to 2 separate consecutive prospective phase 2 studies done by the same group of investigators according to the same protocols in which only the treatment regimens differed. Of the patients 58 were treated with the luteinizing hormone-releasing hormone analogue buserelin alone (0.4 mg. 3 times daily intranasally) and 13 were treated with buserelin combined with cyproterone acetate, a potent antiandrogen (50 mg. 3 times daily orally). The objective of the study was to investigate the efficacy, safety and tolerability of the medication used during at least 12 months by studying adequate endocrine parameters, the rate and duration of response, as well as the rate of progression and possible side effects. All endocrine parameters were studied in 1 laboratory. Modified response criteria of the National Prostatic Cancer Project were used. The endocrine studies showed an effective suppression of plasma testosterone to castration levels by buserelin after an initial increase during the first 2 weeks. Luteinizing hormone and follicle-stimulating hormones were lowered significantly and could not be re-stimulated by the intravenous application of luteinizing hormone-releasing hormone. There was no correlation of plasma testosterone with response and progression. However, a significant correlation existed between higher basal cortisol levels at entry, and after 3 and 6 months, and progression. Response is reported for all patients at the 12-month interval and did not seem to differ among treatment groups. The rate of progression after all patients had been treated for 1 year was 37.9 per cent in the buserelin group and 41 per cent in the buserelin plus cyproterone acetate group. Three early deaths occurred in the buserelin group. Except for impotence, only mild side effects were noted. Our study shows that treatment of metastatic prostatic cancer by means of the luteinizing-hormone-releasing hormone analogue buserelin is safe and effective. The results obtained are compatible with those obtained by castration. In our study a superiority of total androgen withdrawal over testicular suppression alone could not be shown.

Buserelin↗
PubMed1987

Intermediate filament proteins as tissue specific markers in normal and neoplastic testicular tissue.

Normal testicular tissue and primary and metastatic testicular germ cell tumours were examined for their intermediate filament protein (IFP) expression. Seminomas were shown to react with antibodies to vimentin, while non-seminomatous germ cell tumours were strongly positive with antibodies to cytokeratin. In the case of teratocarcinoma, several components of the tumour can be distinguished using a combination of monoclonal and polyclonal antisera in the double-label immunofluorescence technique. We conclude that antibodies to cytokeratin and vimentin can be helpful in the diagnosis of testicular germ cell tumours, especially in the differentiation between seminomas and non-seminomatous testis tumours.

Fluorescent Antibody Technique↗
PubMed1987

Urological trauma and severe associated injuries.

Our experience with 212 cases of urinary tract injury in multiple trauma patients treated between 1972 and 1983 has been analysed and compared with data collected from 441 cases of isolated urinary tract injury during the same period. The following points are emphasised: (1) incidence and severity of urological trauma in multiple injured patients; (2) obstacles in diagnosis and the need for immediate radiographic assessment; (3) lower urinary tract injuries and the need for urinary diversion; (4) differences in therapeutic approach to renal injuries in multiple trauma patients. We paid special attention to the indication for surgical exploration in patients with a renal laceration and severe associated injuries.

Adolescent↗
PubMed1987

Embolization and postinfarction nephrectomy in patients with primary metastatic renal adenocarcinoma.

In a phase-II study of the EORTC GU Group 34 patients with metastatic renal cell carcinoma were treated by angioinfarction and delayed nephrectomy. The mortality of the procedure was 5.8%. One patient had a complete remission. 80% of the patients showed progression within 6 months after nephrectomy. The median survival of the patients was 25 weeks, 65% of the patients died within 1 year after nephrectomy.

Adult↗
PubMed1987

Renal hamartoma associated with renal cell (Grawitz) tumor: another indication that Grawitz tumors are carcinosarcomas.

We report a case of renal hamartoma (angiofibroma) which contained nests of renal cell (Grawitz) tumor and review the literature regarding this subject. We believe that the finding of Grawitz tumor cells within a mesodermal tumor supports our hypothesis that renal cell (Grawitz) tumors are of mixed (mesodermal and endodermal) origin, that is, they show at least one important biological characteristic of carcinosarcomas.

Carcinoma, Renal Cell↗
PubMed1987

fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas.

The recently discovered fur gene encodes a membrane-associated protein with a recognition function. To further characterize the gene, we studied its expression by Northern blot analysis using poly(A)-selected RNA from a variety of organs of African green monkey and rat. The fur gene appeared to be differentially expressed, relatively high levels of fur mRNA being present in specimens of liver and kidney, low levels in brain, spleen, and thymus, and very low levels in heart muscle, lung, and testis. mRNA levels in specimens of human lung tissue without neoplastic lesions were also very low. Similar analyses of primary human lung carcinomas of different histopathological types revealed a highly selective and strong elevation of fur expression in nonsmall cell lung carcinomas, but not in small cell lung carcinomas. These results indicate that fur expression can be used to discriminate between these two types of human lung cancer.

Adenocarcinoma↗
PubMed1987

Emergency management of lower urinary tract injuries.

Trauma to the bladder and (or) urethra mostly occurs in multiple trauma patients and their emergency management often poses problems to both the general surgeon and the urologist. Fourteen cases of bladder rupture and 16 cases of urethral laceration were retrospectively studied, with regard to etiology, trauma mechanism, diagnosis and therapeutic possibilities. Immediate diagnosis and surgical repair are important to reduce mortality and morbidity in cases of bladder rupture. The emergency treatment of urethral injuries is more controversial. The different factors influencing the therapeutic approach are discussed and rational guidelines are suggested to decrease the high complication rate of these injuries.

Adolescent↗
PubMed1987

Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.

Ketoconazole high dose (H.D.) reduces effectively the testosterone production in both adrenals and testes. Its use in the management of (metastatic) prostate cancer has been advocated. Even in relapsing patients after previous hormonal therapy Ketoconazole H.D. could be of value. 28 Relapsing patients, of whom 15 were evaluable at 3 months, have been treated with Ketoconazole H.D. As could be expected, objective response was seen in only a small number of patients followed up till 9 months. Subjective improvement was however noticed in the majority of symptomatic patients. The side effects and toxicity of the therapy remains however a major limitation for the use of Ketoconazole, be it as first line treatment or as therapy for relapsing patients.

Estrogens↗
PubMed1986

Tissue-specific markers in flow cytometry of urological cancers. II. Cytokeratin and vimentin in renal-cell tumors.

Nine primary human renal-cell tumors (RCT), one lymph-node metastasis, 4 human xenografts of a RCT in nude mice and a rat RCT line were analyzed by flow cytometry (FCM) using propidium iodide for DNA analysis and antibodies to cytokeratin and vimentin in the indirect immunofluorescence technique for labelling of specific tumor-cell populations. By means of 2-dimensional FCM analysis, vimentin- and cytokeratin-positive (tumor) cells were compared and their DNA content and proliferative fraction analyzed separately from those of cytokeratin-negative stromal and inflammatory cells. In primary human RCT, 2 subpopulations of cells were detected and analyzed separately. Small numbers of tumor cells with an abnormal DNA stemline were also detected. In addition, co-expression of intermediate filament proteins of both the cytokeratin and the vimentin types was detected in the aneuploid cell population. Comparison of 2 model systems of RCT with primary human RCT revealed a similar pattern of tumor-cell subfractions within these tumors. The 2-parameter FCM analysis permits the detection of subpopulations in complex cell suspensions and the quantification of these fractions, as well as analysis of their cellular DNA content.

Animals↗
PubMed1986

Expression of the human fes cellular oncogene in renal cell tumors.

Renal cell tumors were screened for expression of the cellular oncogenes c-abl, c-fes, c-fms, c-myc, c-ras, and c-sis in dot blot hybridization analysis. Expression of c-ras and c-myc was clearly detectable in most of the 15 tumors that were studied. The c-fes oncogene appeared to be expressed in only two of them. Comparative Southern blot analysis of molecularly cloned human c-fes DNA and genomic DNA of the 15 renal tumors revealed no major genetic differences. Northern blot analysis of poly(A)-selected RNA from the fes-positive tumors with the complete viral v-fes oncogene of the Gardner-Arnstein strain of feline sarcoma virus as a molecular probe revealed hybridization of RNA species of 3.0 and 4.5 kb, respectively. The 3.0 kb c-fes transcript has also been reported in RNA from patients suffering from acute myelogenous leukemia. The 4.5 kb transcript, however, has not been described before and represents either a c-fes-related splicing intermediate or, more likely, a completely processed transcript. The results of this study could imply that human c-fes coding sequences are more extensive than was previously assumed.

Carcinoma, Renal Cell↗
PubMed1986

Dynamics of human renal tumor colony growth in vitro.

Two-layer soft agar cultures from 26 patients with renal cell carcinoma, 21 renal primary lesions and 5 metastatic lesions, were evaluated for tumor colony formation using both dynamic growth curves and static single time point colony counting. Dynamic growth curves markedly increased the number of evaluable tumor cultures. There was no relationship between colony formation and TNM stage of the tumor or renal vein invasion. However, there was a significantly (p less than 0.02) higher rate of colony formation from younger (less than 50 y.) patients than from older patients. Only 2 of 5 tumors tested showed response to one or more cytostatic agents in vitro, both tumors showing response to Adriamycin and one to Cis-platin. Dynamic evaluation of tumor colony formation in soft agar may increase the clinical applicability of the human tumor cloning system both by increasing the number of evaluable cultures and by providing more information about the processes involved in tumor colony formation in vitro.

Adult↗
PubMed1986

Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene.

Comparison of nucleotide sequence data of the 5' region of a fes/fps viral oncogene with those of the v-fes/fps homologous regions of man and cat revealed the position of the 3' portion of an as yet unidentified c-fes/fps exon. Comparative Southern blot and heteroduplex analysis of human and feline DNA immediately upstream of the v-fes/fps homologous regions showed extensive but discontinuous homology over a 9 kbp DNA stretch, which we have designated as fur. Northern blot analysis of mRNA from KG-1 myeloid cells with fes/fps- or fur-specific probes revealed a 3.0 kb fes/fps and a 4.5 kb fur transcript. Analysis of a number of tissues of an adult Wistar Lewis rat for the presence of fur transcripts revealed its differential expression pattern. An 0.95 kbp fes/fps-related and a 2.2 kbp fur-related cDNA recombinant clone were isolated from an oligo(dT)-primed KG-1 cDNA library. Comparative nucleotide sequence analysis of the fes/fps cDNA and its human genomic counterpart indicated that the cDNA contained genetic sequences that were identical to and colinear with exon 15-19 and, furthermore, that the poly(A) addition signal near the 3' end of exon 19 was functional. Similar analysis of the 2.2 kbp fur cDNA indicated that the poly(A) addition signal of the fur transcript was in close proximity of the newly discovered fes/fps exon. The region in between contained a CATT sequence but no 'TATA' box. The fur transcript was characterized by a long noncoding region at its 3' end.

Animals↗
PubMed1986

The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder.

Intravesical and intradermal application of B.C.G. (Bacillus Calmette Guérin) has proven to be effective in the prophylaxis of recurrence of superficial bladder carcinoma after transurethral resection and in the treatment of carcinoma in situ (C.I.S.) in man. Different strains of B.C.G. have been used for this purpose. In this article a new strain of B.C.G. (B.C.G.-R.I.V.M.) has been tested to assess its toxicity. The effects of intravesical and intradermal application of B.C.G.-R.I.V.M. were studied on normal and on coagulated canine urothelium. In this study no general side effects of B.C.G.-R.I.V.M. were seen. Only minor local changes occurred in the bladder wall. Small granulomas were found in the suburothelial tissue. No granulomas or signs of active inflammation were observed in the pelvic lymphnodes, spleen and liver. Because B.C.G.-R.I.V.M. seemed to be a safe agent in the dog we have started to use it for prophylaxis in superficial bladder cancer in man.

Administration, Intravesical↗